Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Mom finds out she has cancer after noticing something was off while breastfeeding - 2Lawsuit claims ChatGPT exacerbated man's delusions leading to murder-suicide
- 3Chris Noth responds to backlash after seemingly shading 'Sex and the City' costar Sarah Jessica Parker: 'It is not news'
- 4A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- 5Pick Your Favored method of transportation
- Energy security rifts widen in Europe
- Warming winters lead to more nitrate pollution in the drinking water near farms
- US bishops officially ban gender-affirming care at Catholic hospitals
- Pick the Ideal Family Feline Variety for Your Home
- West Bank man indicted for extortion, impersonation of IAF pilot, Mossad agent, illegal entry
- Ifo: Job cuts in Germany slowing but not enough for a turnaround
- Instructions to Augment the Presentation of Your Kona SUV
- It May Take a Year to Restore Abu Dhabi Aluminum Output, EGA Says
- Top Pastry: What's Your Sweet Treat of Decision?
